More threads by David Baxter PhD

David Baxter PhD

Late Founder
Marijuana and cannabinoids for medical purposes
Canadian Cancer Society
Retrieved April 24, 2018

Marijuana comes from the cannabis plant. The main psychoactive ingredient in marijuana is THC (delta-9-tetrahydrocannabinol). THC is a type of cannabinoid. There are many other types of cannabinoids in marijuana. Cannabinoids are chemicals that act on certain receptors on cells in our body, especially cells in the central nervous system.

Some people believe that marijuana can help control or relieve some of the symptoms of cancer or the side effects of cancer treatments. But research studies done so far do not give a clear answer about the effectiveness of smoking marijuana. Research does show that some cannabinoids can help with some symptoms and side effects, and drugs containing cannabinoids have been developed to treat pain, nausea and vomiting.

Medical marijuana
Marijuana is an illegal substance in Canada. The Canadian government allows seriously ill people access to marijuana for medical reasons. This is commonly called medical marijuana.
People who want to use marijuana for medical purposes must get a medical document (like a prescription) from a doctor or nurse practitioner. With this document, they can purchase marijuana for medical purposes through licensed producers in Canada. It comes in many forms including dried marijuana, marijuana oil, or fresh marijuana buds or leaves that can be smoked, vaporized, eaten in food or drunk in a tea.

Health Canada’s Access to Cannabis for Medical Purposes Regulations give people with cancer the option to use marijuana for medical purposes to help manage their symptoms and side effects. Talk to your healthcare team about the benefits and risks of using medical marijuana. They can help you decide if it is right for you.

Find out more about Health Canada’s Access to Cannabis for Medical Purposes Regulations.

Relieving symptoms and side effects
Using marijuana, drugs containing cannabinoids or both may help you relax and give you a sense of well-being. But studies on the effectiveness of marijuana have had different results. Some people with cancer may find using marijuana or drugs that contain cannabinoids helps them cope with these symptoms and side effects.

Nausea and vomiting
Several studies have shown that some cannabinoids can relieve nausea, vomiting or both. These are side effects of some cancer treatments, including chemotherapy and radiation therapy.

Nabilone (Cesamet) is a pill that has synthetic cannabinoids. It is approved in Canada to treat nausea and vomiting caused by chemotherapy. It’s sometimes given to people with cancer if standard antinausea drugs do not help relieve these symptoms.

Find out more about nausea and vomiting.

Loss of appetite
Loss of appetite is a common problem for people with cancer. Loss of appetite and weight loss (which is called cachexia when it is severe) often occur together.

Some people find that marijuana can increase their appetite. Several clinical trials looked at marijuana’s effects on appetite or weight loss in people with cancer. To date, these studies haven’t shown for certain that marijuana can effectively improve appetite. Research into whether or not cannabinoids can help people with cancer deal with loss of appetite hasn’t had clear results.

Find out more about loss of appetite.

Pain
Some people claim that marijuana can help relieve long-term (chronic) or severe pain. Research studies done so far do not give a clear answer about the effectiveness of smoking marijuana to relieve pain.

Some clinical trials showed that cannabinoids help reduce pain in some people.

Sativex is a combination of delta-9-THC (Tetranabinex) and cannabidiol (Nabidiolex). It has been approved for use in Canada as a spray that can be applied to the cheek inside the mouth. Savitex may be used to relieve pain from advanced cancer that can’t be relieved with the strongest dose of opioids.

Find out more about pain and opioids.

Side effects and risks of marijuana and cannabinoids for medical purposes
The benefits and risks of marijuana for medical purposes have not been thoroughly reviewed by Health Canada, and individual products have not gone through an approval process. When approving a drug, Health Canada reviews the evidence to make sure that the benefits of the drug outweigh the risks and negative side effects. Talk to your healthcare team if you are thinking about using marijuana for medical purposes or other drugs that contain cannabinoids. There is not enough information to know how using marijuana will interact with drugs and cancer treatments, such as chemotherapy.

Some studies show that smoking marijuana over a long period of time may increase the risk of lung and other cancers. Other studies did not have the same results. Using marijuana may also cause these and other side effects:

  • problems with memory and concentration
  • sensory changes, including a lack of balance and slower reaction times
  • dry mouth
  • rapid heart beat
  • a rise in blood pressure

Ongoing research into marijuana and cannabinoids
Currently, researchers are studying marijuana and drugs that contain cannabinoids to find out more about how they might effectively relieve symptoms of cancer or side effects of cancer treatments. More research is needed to find out the dose and type of marijuana that helps the most with the fewest side effects, the risks and benefits of using medical marijuana for a long time and how medical marijuana might interact with other drugs used to treat cancer.

Researchers are also still trying to find out if marijuana or cannabinoids should be used as medicine to treat certain diseases, including cancer. Research into the effects of cannabinoids on cancer cells in vitro and on experimental animals has shown some promise. But this research is still in the very early stages. Much more study is needed before marijuana or cannabinoids can be used as a cancer treatment.

Read more: http://www.cancer.ca/en/cancer-info...ana-and-cannabinoids/?region=on#ixzz5DdO9GyFJ

References

  • Borgelt LM, Franson KL, Nussbaum AM, Wang GS.. The pharmacologic and clinical effects of medical cannabis. (2013). Pharmacotherapy. 33(2):195-209. doi: 10.1002/phar.1187.
  • Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, MacDonald N, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. (2011). Annals of Oncology. 9):2086-93. Retrieved from: http://annonc.oxfordjournals.org/content/22/9/2086.full.pdf+html.
  • Callaghan RC, Allebeck P, Sidorchuk A.. Marijuana use and risk of lung cancer: a 40-year cohort study. (2013). Cancer Causes and Control. 24(10):1811-20. doi: 10.1007/s10552-013-0259-0.
  • Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: current status and future implications. (2014). Oncotarget. Impact Journals. 5(15):5852-72. Retrieved from: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path=2233.
  • Cridge BJ, Rosengren RJ. Critical appraisal of the potential use of cannabinoids in cancer management. (2013). Cancer Management and Research. Dove Medical Press. 5:301-13. Retrieved from: http://www.dovepress.com/critical-a...ids-in-cancer-mana-peer-reviewed-article-CMAR.
  • Duran M1, Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. (2010). British Journal of Clinical Pharmacology. 70(5):656-63. Retrieved from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997305/pdf/bcp0070-0656.pdf.
  • Farquhar-Smith WP. Do cannabinoids have a role in cancer pain management? (2009). Current Opinion in Supportive and Palliative Care. Wolters Kluwer. 3(1):7-13. doi: 10.1097/SPC.0b013e3283260612.
  • Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. (2009). Lancet. Elsevier, Inc. 374(9698): pp:1383-91. Retrieved from: http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(10)60087-6.pdf.
  • Health Canada, Drugs and Health Products. (2016, August 11). Information on the new Access to Cannabis for Medical Purposes Regulations. Ottawa. Retrieved from: https://www.canada.ca/en/health-can...ical-use-marijuana/medical-use-marijuana.html.
  • Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M. An epidemiologic review of marijuana and cancer: an update. (2015). Cancer Epidemiology, Biomarkers and Prevention. American Association for Cancer Research. 24(1):15-31.
  • Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. (2010). Journal of Pain and Symptom Management. Elsevier. 39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008.
  • Joshi M, Joshi A, Bartter T. Marijuana and lung diseases. (2014). Current Opinion in Pulmonary Medicine. Lippincott Williams & Wilkins. 20(2):173-9. doi: 10.1097/MCP.0000000000000026.
  • Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. (2011). British Journal of Clinical Pharmacology. Wiley. 72(5):735-44. doi: 10.1111/j.1365-2125.2011.03970.x. Retrieved from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243008/pdf/bcp0072-0735.pdf.
  • Machado Rocha FC1, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. (2008). European Journal of Cancer Care. Wiley. 17(5):431-43.
  • Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Research & Management. 19(6):328-35. Retrieved from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4273712/pdf/prm-19-328.pdf.
  • Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. (2011). British Journal of Pharmacology. 163(7):1411-22.
  • Robson PJ.. Therapeutic potential of cannabinoid medicines. (2013). Drug Testing and Analysis. Wiley. doi: 10.1002/dta.1529. (PMID: 24006213).
  • Rooke SE, Norberg MM, Copeland J, Swift W.. Health outcomes associated with long-term regular cannabis and tobacco smoking. (2013). Addictive Behaviours. Elsevier. 38(6):2207-13. doi: 10.1016/j.addbeh.2013.01.013.
  • Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. (2001). BMJ. 323(7303):16-21.
  • Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, Woll PJ, et al. Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. (2015). International Journal of Cancer. Wiley. 136(4):894-903. doi: 10.1002/ijc.29036.

 
Replying is not possible. This forum is only available as an archive.
Top